Genvec (Genvec) Total Current Assets : $4.59 Mil (As of Mar. 2017)

View and export this data going back to 2000. Start your Free Trial

What is Genvec Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Genvec's total current assets for the quarter that ended in Mar. 2017 was $4.59 Mil.

Genvec Total Current Assets Historical Data

The historical data trend for Genvec's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genvec Total Current Assets Chart

Genvec Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Current Assets

Get a 7-Day Free Trial

16.43

6.64

15.24

9.09

7.46

Genvec Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Total Current Assets	Get a 7-Day Free Trial															7.30	10.20	8.94	7.46	4.59

Genvec Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Genvec's Total Current Assets for the fiscal year that ended in Dec. 2016 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	7.165	+	0.022	+	0	+	0.271
	=	7.46

Genvec's Total Current Assets for the quarter that ended in Mar. 2017 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	4.285	+	0.084	+	0	+	0.224
	=	4.59

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Genvec (NAS:GNVC) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Genvec's Liquidation Value for the quarter that ended in Mar. 2017 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.285	-	4.323	+	0.75 * 0.084	+	0.5 * 0
=	0.03

Genvec Total Current Assets Related Terms

Thank you for viewing the detailed overview of Genvec's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Genvec (Genvec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (NAS:GNVC) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.genvec.com

Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.

Executives

Wayne T Hockmeyer	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Michael Richman	director	2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
Marc R Schneebaum	director	GENVEC, INC., 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Stefan Loren	director	3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Douglas J Swirsky	director, officer: President and CEO	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Willam N Kelley	director	MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Mmcap International Inc. Spc	10 percent owner	C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ecor1 Capital Fund Qualified, L.p.	other: See Explanation of Responses	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p.	other: See Explanation of Responses	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Zola P Horovitz	director	C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Cynthia Collins	director, officer: President & CEO	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Adel Mahmoud	director
Joshua Ruch	director	4 DUNE ROAD, EAST QUOGUE NY 11942

Genvec (Genvec) Headlines

From GuruFocus

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus • 08-07-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus • 05-08-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-07-2010

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-06-2009

GenVec Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 03-11-2011